文档介绍：L1EPO, a Novel Podophyllotoxin Derivative es P-glycoprotein-mediated Multidrug Resistance in K562/A02 Cell Line
Hong CHENa,Bo CAOa Jiingzhe Zhanga Shufang BAIa,J Peng-Fei YUb, Jing WANG a,, Hong CHEN*a.
a Medical College of Chinese People’s Armed Police Forces; Tianjin 300162, China: b Key Lab of New Drugs Design and Discovery of Liaoning Province, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University; Shenyang 110016, China.
Abstract
Ineffectiveness of anticancer drugs is frequently observed in cancer chemotherapy. The resistance of tumor cells to various cytotoxic drugs is defined as multidrug resistance (MDR). The purpose of our present study was to investigate the inhibit effects of L1EPO synthesized by our group on P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) in K562/A02 cells. Both the cytotoxicity of pound and its ability to inhibit the K562/A02 cells were determined with SRB assay. Morphologic apoptosis was detected by Hochest33342 staining assay. RT-PCR was used to detect mdr-1 gene transcription and the Western blot assay was used to assess P-gp expression. Interestingly,We found K562/A02 cell line was rendered resistant toward Adriamycin but not towards L1EPO pared with the parental cells. And L1EPO could down regulated mdr-1 gene, and reduced the expression of P-gp and displayed a perfect dose dependent. Moreover, it had less
cytotoxicity in human normal cell lines (fibroblast, VEC), GI50>10μmol/L. Consequently, L1EPO has the potential to es P-glycoprotein-mediated Multidrug Resistance in K562/A02 Cell Line.
Key words
L1EPO, Podophyllotoxin, Derivative, MDR, P-gp
Introduction
Malignant tumors can e resistant to anticancer drugs which often displays muhidrug resistance(MDR). Since MDR was described by Rhoads[1] in 1946, it is a severe challenge for both basic and clinical researches on tumor therapy. Many clinical anticancer drugs such as Anthracyclines antibiotic (actinomycin D, Doxorubicin, Daunorubicin), Alk